LAKE BLUFF, Ill.--(BUSINESS WIRE)--NeoPharm, Inc. (NASDAQ:NEOL) today announced that it has enrolled its first patient in its Phase I clinical trial for LE-DT, a novel, proprietary liposomal delivery system of docetaxel, the active ingredient of Taxotere®, which is used for the treatment of patients with metastatic solid cancer.
